Serum Alanine Aminotransferase
Introduction
Section titled “Introduction”Serum alanine aminotransferase (ALT), also known as serum glutamic-pyruvic transaminase (SGPT), is an enzyme predominantly found in liver cells, but also present in smaller amounts in the kidneys, heart, and skeletal muscles. Its primary biological function is to catalyze the transfer of an amino group from alanine to α-ketoglutarate, producing pyruvate and glutamate. This reaction is a crucial component of amino acid metabolism and the glucose-alanine cycle, which plays a role in gluconeogenesis and nitrogen transport between tissues.
The presence of ALT in the bloodstream typically indicates cellular damage, as the enzyme is released from cells when their membranes are compromised. Because ALT is highly concentrated in the liver, elevated serum ALT levels are a key biomarker for liver health and are widely used to detect and monitor liver injury or disease. Clinically, abnormal ALT levels can signal various conditions, including viral hepatitis, non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease, drug-induced liver injury, and cirrhosis. Studies have identified genetic variants associated with histologic features of nonalcoholic fatty liver disease[1], as well as those influencing plasma levels of liver enzymes [2]. Furthermore, genetic research has explored associations between ALT levels and other health conditions, such as chronic kidney disease[3], fasting glucose levels[4], and type 2 diabetes risk [4], highlighting the enzyme’s broader metabolic relevance [5].
From a social perspective, routine measurement of serum ALT is a common and important component of general health screenings, enabling early detection of potential liver issues before symptoms become severe. Given the rising global prevalence of liver diseases, particularly non-alcoholic fatty liver disease linked to obesity and metabolic syndrome, understanding the factors that influence ALT levels, including genetic predispositions, is increasingly vital for public health. Genetic insights into ALT levels can contribute to personalized risk assessment and the development of targeted preventive strategies for liver and metabolic health.
Limitations
Section titled “Limitations”Understanding the genetic underpinnings of serum alanine aminotransferase amount is subject to several important limitations, primarily concerning the generalizability of findings, methodological constraints, and the complex interplay of environmental factors. Acknowledging these limitations is crucial for interpreting current research and guiding future studies to provide a more comprehensive understanding of this biochemical trait.
Generalizability and Population-Specific Findings
Section titled “Generalizability and Population-Specific Findings”Research into the genetic factors influencing serum alanine aminotransferase amount has largely been conducted in populations of limited demographic diversity, which significantly restricts the broader applicability of the findings. For example, some studies have focused exclusively on White, non-Hispanic individuals or specific cohorts from isolated founder populations or particular geographic regions[1]. This narrow scope means that identified genetic associations may not be universally present or exhibit the same effect sizes across different ancestral groups. Consequently, the interpretation of these results requires caution, as the genetic architecture influencing serum alanine aminotransferase levels could vary considerably in more diverse or underrepresented populations, necessitating validation in varied ancestries.
Methodological and Statistical Considerations
Section titled “Methodological and Statistical Considerations”The methodologies employed in some genome-wide association studies (GWAS) for serum alanine aminotransferase amount present several statistical and design limitations. Studies with relatively small sample sizes can lead to reduced statistical power, potentially resulting in an overestimation of effect sizes for detected associations or an increased risk of missing genuine genetic signals[5]. Furthermore, the use of a subset of all available single nucleotide polymorphisms (SNPs) in genotyping arrays means that some relevant genetic variations may be missed, leading to an incomplete understanding of the genetic landscape due to lack of coverage[6]. The reliance on specific statistical models, such as additive genetic models, might also overlook more complex genetic interactions, and the interpretation of p-values, particularly at extremely low levels, needs careful consideration as their calculation is based on asymptotic assumptions that may not fully apply [5]. Additionally, conducting only sex-pooled analyses, rather than sex-specific ones, risks failing to detect genetic variants that are uniquely associated with serum alanine aminotransferase levels in either males or females[6].
Environmental and Phenotypic Complexity
Section titled “Environmental and Phenotypic Complexity”The genetic landscape of serum alanine aminotransferase amount is further complicated by environmental and phenotypic factors that are not always comprehensively accounted for in research. Confounding variables such as age, body mass index (BMI), and various comorbid diseases are known to influence biochemical traits and, if not adequately adjusted for, can obscure true genetic effects or introduce spurious associations[1]. Some analyses have explicitly noted a lack of further adjustment beyond basic genetic models, which could leave reported associations susceptible to environmental or lifestyle influences[5]. Moreover, the broad definition of serum alanine aminotransferase amount as a single phenotype might mask more specific biological pathways, with studies suggesting that exploring intermediate phenotypes on a continuous scale could provide more detailed insights into affected pathways[5]. This implies that while genetic variants may be identified, their precise functional roles and interactions within the broader biological system, particularly in the context of gene-environment interplay, often remain largely unknown.
Variants
Section titled “Variants”Genetic variations play a significant role in determining an individual’s serum alanine aminotransferase (ALT) levels, a key indicator of liver health. These variants can influence gene expression, protein function, or metabolic pathways, contributing to inter-individual differences in ALT. Key genes associated with ALT levels includeGPT, PNPLA3, and ERLIN1, among others, which have diverse functions ranging from enzyme activity to lipid metabolism and immune response.
Variants in the GPTgene, which encodes the alanine aminotransferase enzyme itself, directly impact the production and activity of ALT. Single nucleotide polymorphisms (SNPs) likers147998249 , rs147672961 , and rs531504907 can lead to altered enzyme kinetics or expression levels, influencing the baseline amount of ALT found in the bloodstream. Studies have identified genetic associations with plasma ALT levels, highlighting the role of such variants in liver enzyme regulation oplasmic reticulum function and lipid raft organization . As a key biomarker trait, ALT is often investigated in genome-wide association studies to understand its genetic underpinnings and its role as an intermediate phenotype in various physiological and pathological processes [7]. This enzyme plays a crucial role in amino acid metabolism, primarily within the liver, and its presence in serum reflects cellular integrity.
Key Variants
Section titled “Key Variants”| RS ID | Gene | Related Traits |
|---|---|---|
| rs147998249 rs147672961 rs531504907 | GPT | serum alanine aminotransferase amount aspartate aminotransferase to alanine aminotransferase ratio |
| rs112635299 | SERPINA2 - SERPINA1 | forced expiratory volume, response to bronchodilator FEV/FVC ratio, response to bronchodilator coronary artery disease BMI-adjusted waist circumference C-reactive protein measurement |
| rs738409 rs738408 rs3747207 | PNPLA3 | non-alcoholic fatty liver disease serum alanine aminotransferase amount Red cell distribution width triacylglycerol 56:6 measurement alcoholic liver cirrhosis |
| rs12940684 | TNFSF12, TNFSF12-TNFSF13 | body fat percentage sex hormone-binding globulin measurement aspartate aminotransferase measurement serum alanine aminotransferase amount |
| rs28929474 | SERPINA1 | forced expiratory volume, response to bronchodilator FEV/FVC ratio, response to bronchodilator alcohol consumption quality heel bone mineral density serum alanine aminotransferase amount |
| rs2862954 rs1408579 rs10883451 | ERLIN1 | serum alanine aminotransferase amount aspartate aminotransferase measurement sex hormone-binding globulin measurement testosterone measurement alcohol use disorder measurement, alcohol consumption quality |
| rs2980888 rs28601761 rs2954021 | TRIB1AL | BMI-adjusted waist circumference kit ligand amount anxiety measurement, triglyceride measurement depressive symptom measurement, non-high density lipoprotein cholesterol measurement triglyceride measurement, depressive symptom measurement |
| rs11642015 rs56094641 rs17817449 | FTO | diastolic blood pressure systolic blood pressure pulse pressure measurement mean arterial pressure blood urea nitrogen amount |
| rs11122450 | GALNT2 | platelet-to-lymphocyte ratio depressive symptom measurement, non-high density lipoprotein cholesterol measurement body fat percentage high density lipoprotein cholesterol measurement triglyceride measurement |
| rs10733608 rs7041363 rs7043196 | AKNA | serum alanine aminotransferase amount level of beta-ureidopropionase in blood total cholesterol measurement level of meprin A subunit alpha in blood high density lipoprotein cholesterol measurement |
Measurement Approaches and Quantitative Assessment
Section titled “Measurement Approaches and Quantitative Assessment”The amount of serum alanine aminotransferase is typically measured in units per liter (U/L)[1]. This biochemical trait is assessed from human serum samples, often as part of broader metabolite profiling efforts [5]. Operational definitions for ALT involve these quantitative measurements, which allow for its analysis as a continuous variable. For instance, studies have reported median ALT values in cohorts, such as 51 U/L with an interquartile range of 31–76 U/L in a specific group of individuals [1], demonstrating its precise, quantitative nature. The continuous scale approach to measuring ALT is particularly valuable in genetic studies, as it can provide more detailed insights into potentially affected pathways compared to purely categorical classifications [5]. This dimensional perspective allows for a nuanced understanding of variations in ALT levels across populations and their associations with genetic variants.
Clinical Significance and Classification in Disease Context
Section titled “Clinical Significance and Classification in Disease Context”Elevated serum alanine aminotransferase levels serve as a significant indicator in clinical diagnostics, particularly for liver health. For example, specific amounts of ALT are associated with histologic features of nonalcoholic fatty liver disease (NAFLD)[1]. While the context does not explicitly define diagnostic cut-offs for disease classification, the reported median and interquartile ranges suggest a spectrum of values that can be used to assess health status or disease severity[1]. The classification of ALT levels in a disease context often involves considering its continuous nature, where higher values may indicate greater liver injury or disease progression[5]. Its utility as a biomarker in conditions like NAFLD underscores its importance for both clinical diagnosis and research criteria, serving as a critical component in understanding complex genetic traits and their manifest intermediate phenotypes [1].
Causes of Serum Alanine Aminotransferase Amount
Section titled “Causes of Serum Alanine Aminotransferase Amount”The amount of serum alanine aminotransferase (ALT) is a crucial biomarker reflecting liver health, and its levels are influenced by a complex interplay of genetic, environmental, developmental, and acquired factors. Understanding these diverse causal pathways is essential for comprehensive health assessment.
Genetic Predisposition and Polygenic Influence
Section titled “Genetic Predisposition and Polygenic Influence”Genetic factors significantly contribute to the variability in serum alanine aminotransferase levels. Genome-wide association studies (GWAS) have identified specific genetic loci associated with biochemical traits, including those related to liver function. For instance, variants associated with histologic features of nonalcoholic fatty liver disease (NAFLD) directly contribute to altered liver enzyme levels, reflecting underlying liver health[1]. Furthermore, specific single nucleotide polymorphisms (SNPs) within genes like RAP1GDS1 on chromosome 4 (rs10516430 ) and ZCCHC16 on chromosome X (rs5982533 ) have been linked to variations in biochemical traits, indicating a direct genetic component influencing these serum markers [8].
The amount of serum ALT is often a polygenic trait, meaning it is influenced by the combined effects of numerous genetic variants, each contributing a small effect. While complex traits are typically driven by many genes, the principles derived from studying Mendelian traits can inform genome-wide approaches to understand the pathways involved in complex genetic traits [9]. Studies employing additive genetic models analyze the cumulative impact of minor alleles, revealing how this polygenic risk contributes to the continuous spectrum of biochemical phenotypes [5].
Environmental Modulators and Lifestyle Factors
Section titled “Environmental Modulators and Lifestyle Factors”Environmental factors, encompassing lifestyle, diet, and various exposures, play a substantial role in modulating serum alanine aminotransferase levels. Research indicates that the variability and heritability of human plasma N-glycome, a related biochemical trait, are influenced by environmental determinants[8]. This suggests that broader lifestyle choices, including dietary patterns and levels of physical activity, can significantly impact liver health and, consequently, ALT levels.
Specific environmental exposures and geographic influences can also contribute to variations in ALT. While not exhaustively detailed for ALT in the provided context, studies conducted in distinct populations, such as those from Korcula Island, Croatia, or isolated founder populations, highlight the potential for unique environmental or lifestyle factors prevalent in these regions to shape population-specific differences in biochemical markers[8]. These influences collectively contribute to the observed range of ALT levels across different individuals and communities.
Complex Gene-Environment and Developmental Interactions
Section titled “Complex Gene-Environment and Developmental Interactions”The amount of serum alanine aminotransferase is shaped by intricate interactions between an individual’s genetic predisposition and their environmental exposures. Genetic susceptibilities, such as variants influencing the risk of nonalcoholic fatty liver disease, can be significantly amplified or mitigated by environmental triggers like diet, physical activity, and other lifestyle choices[1]. This dynamic interplay means that individuals with certain genetic backgrounds may exhibit a heightened susceptibility to elevated ALT levels when exposed to specific environmental risk factors, highlighting the personalized nature of liver health.
Developmental and epigenetic factors also contribute to the long-term programming of metabolic pathways that can influence ALT levels. Although the provided context does not explicitly detail specific early life influences, DNA methylation, or histone modifications directly for serum ALT, the broader understanding of complex traits suggests their potential involvement. The continuous scale of intermediate phenotypes, which includes metabolic markers like ALT, can be modulated by these early life and epigenetic mechanisms, shaping an individual’s metabolic profile throughout their lifespan[5].
Comorbidities and Acquired Influences
Section titled “Comorbidities and Acquired Influences”Elevated serum alanine aminotransferase levels are frequently associated with or influenced by various comorbid health conditions. For instance, genetic loci linked to susceptibility to type 2 diabetes and chronic kidney disease also influence other metabolic and biochemical traits, which can indirectly affect liver function and ALT[10]. Nonalcoholic fatty liver disease (NAFLD), a common comorbidity often linked to metabolic syndrome, is a direct and significant cause of altered ALT, with specific genetic variants contributing to its histologic features[1].
Beyond chronic conditions, the amount of serum ALT can also be affected by the use of medications and age-related physiological changes. Research has highlighted the role of age and comorbid diseases in the association of genetic variants with conditions such as chronic kidney disease and kidney stones, demonstrating how these broader factors can impact various biochemical markers[3]. While specific medications causing ALT elevation are not detailed, the process of aging itself, with its associated changes in metabolic health and liver function, can lead to variations in serum ALT levels across the lifespan.
Alanine Aminotransferase (ALT) in Hepatic Metabolism
Section titled “Alanine Aminotransferase (ALT) in Hepatic Metabolism”Alanine aminotransferase (ALT) is an enzyme that plays a critical role in amino acid metabolism, facilitating the conversion of alanine and α-ketoglutarate into pyruvate and glutamate. This process is vital for gluconeogenesis, where amino acids are converted into glucose, and for the detoxification of ammonia. Primarily concentrated in the liver, ALT’s enzymatic activity is central to hepatocyte function, making it a key indicator of liver metabolic health. Its presence in serum reflects the integrity of liver cells, as cellular damage can lead to its release into the bloodstream.
Genetic Determinants of Serum ALT Levels
Section titled “Genetic Determinants of Serum ALT Levels”Genetic mechanisms significantly influence the amount of alanine aminotransferase found in serum, a trait often explored through genome-wide association studies (GWAS). These studies identify specific genetic variants that are associated with variations in ALT levels, linking genetic predispositions to metabolic characteristics. The identified genetic loci can affect gene functions, regulatory elements, or gene expression patterns that ultimately control the synthesis or breakdown of the ALT enzyme. Understanding these genetic influences is crucial for a more personalized approach to health, integrating an individual’s genotype with their unique metabolic profile[5].
ALT as a Biomarker for Liver Health and Disease
Section titled “ALT as a Biomarker for Liver Health and Disease”Serum alanine aminotransferase serves as a widely recognized biomarker for assessing liver health and detecting pathophysiological processes. Elevated levels typically indicate liver cell injury or inflammation, signaling a disruption in hepatic homeostasis. Research has specifically linked genetic variants associated with serum ALT amounts to the histologic features of nonalcoholic fatty liver disease (NAFLD)[1]. This connection underscores ALT’s importance in diagnosing and monitoring the progression of liver diseases, reflecting the extent of damage and the body’s compensatory responses within the liver.
Systemic Metabolic Interplay
Section titled “Systemic Metabolic Interplay”Beyond its specific role in the liver, serum ALT is considered an important intermediate phenotype that provides insights into broader systemic metabolic pathways. Its levels contribute to an individual’s overall “metabolite profile” in human serum, which can reflect the intricate interconnections among various metabolic processes throughout the body [5]. Genetic variations influencing ALT can therefore have wider implications for an individual’s metabolic health, impacting how nutrients are processed and potentially influencing susceptibility to various metabolic conditions. The comprehensive analysis of these metabolomic and genetic characteristics aids in a deeper understanding of human physiology and disease risk[5].
Pathways and Mechanisms
Section titled “Pathways and Mechanisms”Metabolic Pathways and Glucose Homeostasis
Section titled “Metabolic Pathways and Glucose Homeostasis”Alanine aminotransferase (ALT) plays a pivotal role in amino acid metabolism, particularly in the liver, by facilitating the conversion of alanine to pyruvate, a key substrate for gluconeogenesis. Genetic variants influencing fasting glucose levels and susceptibility to type 2 diabetes can impact the metabolic flux through pathways involving ALT, thereby affecting its activity or expression[4], [11], [12], [13], [14]. This intricate metabolic regulation ensures the maintenance of glucose homeostasis, where alterations can signify shifts in energy metabolism and substrate utilization. The balance between alanine catabolism and glucose production is crucial, and its disruption can be reflected in serum ALT amounts.
Hepatic Stress and Nonalcoholic Fatty Liver Disease
Section titled “Hepatic Stress and Nonalcoholic Fatty Liver Disease”Serum alanine aminotransferase amount is a widely recognized biomarker for liver health, with elevated levels often indicating hepatocellular injury. Genetic variants associated with histologic features of nonalcoholic fatty liver disease (NAFLD) suggest a direct link between genetic predisposition and liver pathology[1]. In NAFLD, metabolic dysregulation within hepatocytes, including altered lipid metabolism and oxidative stress, can lead to cell damage and subsequent release of intracellular ALT into the circulation. This dysregulation reflects compromised cellular integrity and a disrupted metabolic environment, impacting the equilibrium of liver enzyme levels.
Systemic Integration and Pathway Crosstalk
Section titled “Systemic Integration and Pathway Crosstalk”The amount of serum alanine aminotransferase is not solely determined by liver-specific mechanisms but is also influenced by broader systemic interactions and pathway crosstalk. Genetic variations associated with general metabolite profiles, kidney function, and other biochemical traits highlight a complex network of influences on ALT levels[5], [10], [3], [7], [8]. For instance, kidney dysfunction can affect the clearance of various substances, potentially altering the systemic balance that impacts liver enzyme concentrations. Such systems-level integration underscores how changes in one physiological system can cascade to affect others, leading to emergent properties in biomarker levels like ALT.
Genetic Regulation and Disease Susceptibility
Section titled “Genetic Regulation and Disease Susceptibility”Genetic factors play a crucial role in regulating the baseline and pathological serum alanine aminotransferase amounts, influencing an individual’s susceptibility to conditions that elevate ALT. Genome-wide association studies have identified specific genetic loci linked to various metabolic and physiological traits, including those related to liver function, glucose homeostasis, and inflammatory markers[1], [5], [10], [11], [13]. These genetic variants can affect gene expression, protein stability, or enzymatic activity through various regulatory mechanisms, ultimately modulating the cellular processes that govern ALT levels. Understanding these genetic underpinnings can provide insights into potential therapeutic targets for managing conditions characterized by abnormal ALT.
Clinical Relevance
Section titled “Clinical Relevance”The serum alanine aminotransferase (ALT) amount is a widely utilized biomarker, primarily reflecting liver health, but also serving as an indicator for broader metabolic status and risk for various comorbidities. Its clinical utility spans diagnostic applications, monitoring disease progression, and informing personalized medical approaches.
Diagnostic and Monitoring Utility
Section titled “Diagnostic and Monitoring Utility”Serum alanine aminotransferase (ALT) is a crucial enzyme in liver function assessment, with elevated levels typically indicating hepatocellular injury[7]. This makes it a primary diagnostic tool for various liver conditions, including nonalcoholic fatty liver disease (NAFLD), where genetic variants are associated with specific histological features[1]. Monitoring ALT levels over time is essential for tracking disease progression, evaluating treatment efficacy, and identifying acute or chronic liver insults. The interpretation of ALT levels must consider several confounding factors, as its amount can be influenced by age, sex, body mass index (BMI), alcohol intake, diabetes status, and lipid profiles[7].
Association with Metabolic and Related Comorbidities
Section titled “Association with Metabolic and Related Comorbidities”Beyond direct liver injury, elevated serum ALT amounts are strongly associated with components of metabolic syndrome, highlighting its role as a marker for systemic metabolic dysfunction. These comorbidities include type 2 diabetes, obesity, hypertension, and dyslipidemia[7]. For instance, studies have shown a clear link between ALT levels and diabetes-related traits, as well as factors correlating with chronic kidney disease (CKD) such as hypertension, diabetes, smoking, obesity, and low HDL cholesterol[15]. The association of ALT with these overlapping phenotypes underscores its significance in assessing overall cardiometabolic health and identifying individuals at risk for multifaceted health complications.
Risk Stratification and Personalized Medicine
Section titled “Risk Stratification and Personalized Medicine”The serum ALT amount plays a valuable role in risk stratification by helping identify individuals at higher risk for developing or experiencing progression of metabolic and liver diseases [7]. Integrating ALT levels with other metabolic indicators and genetic information can enhance the precision of risk assessment, allowing for more personalized prevention strategies. This approach, combining metabolic characterization with genotyping, represents a step towards personalized healthcare, enabling tailored interventions based on an individual’s unique biological profile [5]. However, it is important to note that some studies examining genetic variants associated with histologic features of NAFLD have been conducted in specific populations, such as exclusively White (non-Hispanic) individuals, which may limit the generalizability of certain findings across diverse patient populations [1].
Frequently Asked Questions About Serum Alanine Aminotransferase Amount
Section titled “Frequently Asked Questions About Serum Alanine Aminotransferase Amount”These questions address the most important and specific aspects of serum alanine aminotransferase amount based on current genetic research.
1. If my parents have liver problems, will my ALT be high too?
Section titled “1. If my parents have liver problems, will my ALT be high too?”Your family history can definitely play a role. Genetic predispositions are increasingly recognized as influencing your ALT levels and susceptibility to liver conditions. While lifestyle matters, your inherited genes can make you more or less prone to elevated ALT, even if you try to live healthily.
2. I eat well and exercise, but why is my ALT still high?
Section titled “2. I eat well and exercise, but why is my ALT still high?”It can be frustrating when your ALT is high despite a healthy lifestyle. This is where genetics come in; some individuals have genetic variations that make them more prone to higher ALT levels or certain liver conditions, regardless of their good habits. Other underlying health issues not directly related to diet or exercise can also contribute.
3. Does my family’s background affect my ALT levels?
Section titled “3. Does my family’s background affect my ALT levels?”Yes, your ancestry can influence your ALT levels. Research shows that genetic factors affecting ALT can vary significantly across different ethnic and ancestral groups. Findings from studies on one population might not apply universally, highlighting why personalized risk assessment based on your background is important.
4. Does my age affect what’s considered a normal ALT for me?
Section titled “4. Does my age affect what’s considered a normal ALT for me?”Age can indeed be a factor influencing ALT levels. As we age, our bodies change, and this can sometimes affect how our liver functions or how other health conditions, which often become more prevalent with age, impact our ALT. Doctors typically consider age along with other factors when interpreting your results.
5. Why do doctors link my weight to my ALT levels?
Section titled “5. Why do doctors link my weight to my ALT levels?”There’s a strong connection between weight and ALT because obesity is a major risk factor for conditions like non-alcoholic fatty liver disease (NAFLD). NAFLD can cause liver cell damage, leading to higher ALT levels. Genetic factors can also influence your susceptibility to both obesity and NAFLD.
6. Can my high blood sugar also make my ALT levels high?
Section titled “6. Can my high blood sugar also make my ALT levels high?”Absolutely. High ALT levels are often associated with conditions like elevated fasting glucose and an increased risk of type 2 diabetes. Genetic research has shown direct links between variations in genes influencing ALT and those related to glucose metabolism, highlighting a broader metabolic connection.
7. Can I have high ALT without feeling sick?
Section titled “7. Can I have high ALT without feeling sick?”Yes, you absolutely can. One of the main reasons routine ALT checks are so important is to detect potential liver issues early, often before any symptoms appear. Liver damage can progress silently, making these screenings crucial for early intervention.
8. Why do some people have good ALT even with bad habits?
Section titled “8. Why do some people have good ALT even with bad habits?”This often comes down to individual genetic differences. Some people are genetically more resilient to the effects of unhealthy habits on their liver and metabolism. They might have genetic variations that protect them, while others are genetically more susceptible to damage and higher ALT from similar exposures.
9. Does drinking alcohol affect my ALT differently than my friend’s?
Section titled “9. Does drinking alcohol affect my ALT differently than my friend’s?”While alcohol generally impacts the liver, your genetic makeup can influence how your body processes alcohol and your susceptibility to alcoholic liver disease. This means that for the same amount of alcohol, your ALT response might differ from your friend’s due to these underlying genetic variations.
10. What can I do to keep my ALT healthy if it runs in my family?
Section titled “10. What can I do to keep my ALT healthy if it runs in my family?”Understanding your family history is a great first step. While you can’t change your genes, knowing your genetic predispositions allows for more targeted preventive strategies. Focusing on a healthy diet, maintaining a healthy weight, limiting alcohol, and regular check-ups become even more important for managing your risk.
This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.
Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.
References
Section titled “References”[1] Chalasani, N. “Genome-wide association study identifies variants associated with histologic features of nonalcoholic Fatty liver disease.”Gastroenterology, vol. 139, no. 5, 2010, pp. 1530-1540. PubMed, PMID: 20708005.
[2] Yuan, X., et al. “Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes.” The American Journal of Human Genetics, vol. 83, no. 4, 2008, pp. 520–528.
[3] Gudbjartsson, D. F. et al. “Association of variants at UMOD with chronic kidney disease and kidney stones-role of age and comorbid diseases.”PLoS Genet, vol. 6, no. 7, 2010, e1001039.
[4] Chambers, J. C., et al. “Common genetic variation near melatonin receptor MTNR1B contributes to raised plasma glucose and increased risk of type 2 diabetes among Indian Asians and European Caucasians.”Diabetes, vol. 58, no. 10, 2009, pp. 2413-2418.
[5] Gieger, C. “Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum.”PLoS Genet, 2008.
[6] Yang, Q. et al. “Genome-wide association and linkage analyses of hemostatic factors and hematological phenotypes in the Framingham Heart Study.”BMC Med Genet, vol. 8, 2007, p. 55.
[7] Benjamin, E. J. et al. “Genome-wide association with select biomarker traits in the Framingham Heart Study.” BMC Medical Genetics, vol. 8, 2007, p. 58. PMID: 17903293.
[8] Zemunik, T. “Genome-wide association study of biochemical traits in Korcula Island, Croatia.” Croat Med J, vol. 50, no. 1, 2009, pp. 32-39. PubMed, PMID: 19260141.
[9] Lowe, J. K. et al. “Genome-wide association studies in an isolated founder population from the Pacific Island of Kosrae.” PLoS Genet, vol. 5, no. 2, 2009, e1000365.
[10] Kottgen, A. “New loci associated with kidney function and chronic kidney disease.”Nat Genet, vol. 42, no. 5, 2010, pp. 376-381. PubMed, PMID: 20383146.
[11] Dupuis, J. “New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk.”Nat Genet, vol. 42, no. 2, 2010, pp. 105-111. PubMed, PMID: 20081858.
[12] Meigs, J. B., et al. “Genome-wide association with diabetes-related traits in the Framingham Heart Study.” BMC Med Genet, vol. 8, suppl. 1, 2007, S16.
[13] Prokopenko, I. “Variants in MTNR1B influence fasting glucose levels.”Nat Genet, vol. 41, no. 1, 2009, pp. 77-81. PubMed, PMID: 19060907.
[14] Xing, C. “A weighted false discovery rate control procedure reveals alleles at FOXA2 that influence fasting glucose levels.”Am J Hum Genet, vol. 86, no. 3, 2010, pp. 440-446. PubMed, PMID: 20152958.
[15] Hwang, S. J., et al. “A genome-wide association for kidney function and endocrine-related traits in the NHLBI’s Framingham Heart Study.” BMC Med Genet, vol. 8, suppl. 1, 2007, S15.